A Study to Assess Safety and Improvement in Skin Barrier After Using 2 Facial Sunscreens in Adults With Sensitive Skin

Inclusion Criteria: * Participants vaccinated against coronavirus disease 2019 (COVID-19) * Participants of any gender * Participants of any ethnicities according to Brazilian Institute of Geography and Statistics (IBGE) criteria * Phototype II to IV according to Fitzpatrick's classification * Participants - in good health based on medical history reported by the subject * Participants presenting intact skin on the face, with the exception of clinical signs characteristic of sensitive skin * Participants who declare themselves as having sensitive skin (according to the Institute's sensitive skin questionnaire, completed in the recruitment phase and reconfirmed by the physician on the day of inclusion) * Able to read, write, speak and understand Portuguese (able to read and understand the documents delivered and what is explained to them) * Participants who agree to maintain their cosmetic habits during the study period * Participants who agree to maintain their cosmetic habits during the study period * Participant who signed the Informed Consent Document (ICD) * Agreement to adhere to the procedures and requirements of the study and to attend the Site on the day(s) and time(s) determined for the assessments * Participant that intend to complete the study and is willing and able to follow all study instructions Exclusion Criteria: * Participants that have had allergies or adverse reactions to common topical skincare products, including sunscreens, medications, or other products that the investigator considers relevant * Participants that present a skin condition that may influence the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, intense erythema, or active skin cancer). Mild erythema and xerosis associated with a sensitive skin condition are acceptable for eligibility * Participants that present primary/secondary lesions (for example: scars, ulcers, vesicles, vitiligo) or tattoos on the test areas * Participants that have undertaken cosmetic or dermatological treatment, invasive or non-invasive, in the test areas within 3 weeks before the beginning of the study and during the study * Participants that have self-reported Type 1 or Type 2 diabetes or are taking insulin or another anti-diabetic medication * Participants that are taking a medication that would mask an adverse event (AE) or influence the study results, including: Immunosuppressive or steroidal drugs within 2 months before Visit 1; Non-steroidal anti-inflammatory drugs within 5 days before Visit 1; Antihistamines within 2 weeks before Visit 1. If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the study physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication" * Participants that are self-reported to be pregnant or planning to become pregnant during the study * Participants that have a history of a health condition/situation which may put the individual at significant risk, influence the study results, or interfere significantly with the individual's participation in the study * Participants that are simultaneously participating in any other study * Participants that are employees/contractors or immediate family members of the principal investigator (PI), study site, or sponsor * History of non-adherence or unwillingness to adhere to the study protocol * Any condition not previously mentioned that, in the opinion of the PI, may compromise the study evaluation